Physician profile
James Travis Burt
NPI 1619983962
$474.78
in general payments reported to CMS, 2019-2025
15 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $35.78 · 2021: $91.38 · 2022: $18.33 · 2024: $65.71 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocomposites INC | $103.95 | 2025 | Stimulan |
| Medtronic, INC. | $47.14 | 2021 | |
| Depuy Synthes Sales INC. | $44.36 | 2024 | Synthecel |
| Medtronic USA, INC. | $38.51 | 2019-2020 | |
| Smith+Nephew, INC. | $32.97 | 2019-2025 | Pico 14, "Acticoat 4"" X 4""", Pico 7 |
| Globus Medical, INC. | $30.79 | 2021 | |
| Lemaitre Vascular, INC. | $29.39 | 2019 | |
| Solventum Corporation | $23.12 | 2025 | Prevena, V.A.C.Ulta |
| Biodelivery Sciences International, INC. | $22.92 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $21.35 | 2024 | Andexxa |
| Baudax Bio INC. | $18.33 | 2022 | |
| Portola Pharmaceuticals, LLC | $17.48 | 2019 | |
| Si-Bone, INC. | $17.26 | 2019 | |
| Providence Medical Technology, INC. | $13.76 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Burt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.